1. Home
  2. BNTX

BNTX

BioNTech SE

Logo BioNTech SE

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Founded: 2008 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 20.8B IPO Year: 2019
Target Price: $127.58 AVG Volume (30 days): 633.9K
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 4.09 EPS Growth: -89.86
52 Week Low/High: $85.21 - $131.52 Next Earning Date: 05-06-2024
Revenue: $4,243,333,333 Revenue Growth: -77.94%
Revenue Growth (this year): -24.74% Revenue Growth (next year): 1.36%

Share on Social Networks: